Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Clinician Scientist - Phase 1

University of Toronto

$172,500.00

Host-pathogen interactions in malaria and tuberculosis: experimental models and translation to novel adjunctive therapies

EF 2009-10

Résumé
Tuberculosis and malaria are leading causes of disease and death around the world. Understanding how the body fights these diseases, how they may interact, and looking for new treatments may have important implications for human health. The first two questions we explored were: (1) does malaria make mycobacterial (tuberculosis-like) disease worse; and (2) does a cell surface molecule called CD36 contribute to the body¿s defences against mycobacteria? We used cells and mouse infections to model aspects of human disease. We showed that malaria exacerbates mycobacterial infection, which may be important for people living in areas where both diseases are common who may become co-infected (manuscript submitted, J Infect Dis). We next showed that mycobacterial infection is attenuated in CD36 deficient mice which may explain why many people living in areas where tuberculosis is common have genetic mutations in CD36 (manuscript submitted, Am J Pathol). We are proposing new experiments to further examine the mechanism of this finding. Next, we are designing a clinical trial of another treatment strategy for severe malaria, inhaled nitric oxide (iNO). We are proposing this human trial because animal studies and a human trial using the NO donor L-arginine have suggested that NO is effective against malaria, and clinical experience and numerous trials of iNO for other conditions have shown that its use is safe in humans. We have validated a way to objectively measure malaria severity in a recently published mansucript (Lovegrove et al.,PLoS ONE, 2009), which will serve as a primary endpoint of this trial. This program of research is multi-disciplinary and spans a wide range of techniques, all the way from bench research and animal models to direct translation to human disease with a clinical trial of an innovative adjuvant treatment for severe malaria.
Programme
CIHR Clinician Scientist - Phase 1
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
197183
Name
Hawkes Michael T
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Clinician Scientist
Projecttitle
Host-pathogen interactions in malaria and tuberculosis: experimental models and translation to novel adjunctive therapies
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$172,500
Cihrequipment2
$0
Programname2
CIHR Clinician Scientist - Phase 1
Keyworddelim
Innate Immunity; Malaria; Mycobacteria; Nitric Oxide; Tuberculosis
Abstract
Tuberculosis and malaria are leading causes of disease and death around the world. Understanding how the body fights these diseases, how they may interact, and looking for new treatments may have important implications for human health. The first two questions we explored were: (1) does malaria make mycobacterial (tuberculosis-like) disease worse; and (2) does a cell surface molecule called CD36 contribute to the body¿s defences against mycobacteria? We used cells and mouse infections to model aspects of human disease. We showed that malaria exacerbates mycobacterial infection, which may be important for people living in areas where both diseases are common who may become co-infected (manuscript submitted, J Infect Dis). We next showed that mycobacterial infection is attenuated in CD36 deficient mice which may explain why many people living in areas where tuberculosis is common have genetic mutations in CD36 (manuscript submitted, Am J Pathol). We are proposing new experiments to further examine the mechanism of this finding. Next, we are designing a clinical trial of another treatment strategy for severe malaria, inhaled nitric oxide (iNO). We are proposing this human trial because animal studies and a human trial using the NO donor L-arginine have suggested that NO is effective against malaria, and clinical experience and numerous trials of iNO for other conditions have shown that its use is safe in humans. We have validated a way to objectively measure malaria severity in a recently published mansucript (Lovegrove et al.,PLoS ONE, 2009), which will serve as a primary endpoint of this trial. This program of research is multi-disciplinary and spans a wide range of techniques, all the way from bench research and animal models to direct translation to human disease with a clinical trial of an innovative adjuvant treatment for severe malaria.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hawkes, Michael T
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $172,500~ $0~